ejpmr, 2025, 12(3), 628-633

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

SJIF Impact Factor 7.065

Review Article

ISSN 2394-3211

EJPMR

COMBATTING ANTIMICROBIAL RESISTANCE: ADVANCES IN DRUG DESIGN AND NOVEL TREATMENT STRATEGIES

Uppu Manasa[1]*, P. Sailaja[2] and Y. Prapurnachandra[3]

[1]Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.

[2]Associate Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.

[3]Professor & Principal, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.

***Corresponding Author: Uppu Manasa**

Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India. **Email ID:** manasauppu349@gmail.com,

Article Received on 06/02/2025 **Article Revised on 26/02/2025** **Article Accepted on 16/03/2025**

ABSTRACT

Antimicrobial resistance (AMR) has emerged as a critical global health challenge, significantly contributing to increased morbidity and mortality. The primary mechanisms of resistance include restricted drug uptake, modification of drug targets, enzymatic inactivation, and active efflux of antimicrobial agents. These resistance strategies can be either intrinsic to microorganisms or acquired through horizontal gene transfer. Among these, efflux transporters play a vital role in bacterial defense, actively expelling antibiotics and other toxic compounds from the cytoplasm or surrounding membranes into the external environment. Based on their sequence similarities, substrate specificity, and energy sources, bacterial multidrug efflux pumps are classified into seven major families: ATP-binding cassette (ABC), resistance-nodulation-division (RND), major facilitator superfamily (MFS), small multidrug resistance (SMR), multidrug and toxic compound extrusion (MATE), proteobacterial antimicrobial compound efflux (PACE), and AbgT transporters. These transporters vary in function, with some exhibiting specificity for a single compound while others accommodate a wide range of structurally diverse molecules. Gram-negative bacteria, which comprise the majority of pathogens on the World Health Organization (WHO) priority list, exhibit higher resistance levels than Gram-positive bacteria due to their unique cell wall structure. This makes infections caused by Gram-negative bacteria more difficult to treat, leading to severe health consequences. The continuous evolution and spread of AMR pose a serious threat, rendering several infectious diseases increasingly difficult or even impossible to treat. Therefore, understanding the molecular mechanisms underlying resistance and developing innovative therapeutic approaches are crucial to combating AMR and reducing its global impact.

KEYWORDS: Antimicrobial resistance (AMR), Multidrug efflux pumps, Gram-negative bacteria, Drug resistance mechanisms, Novel antimicrobial strategies.

INTRODUCTION

Antimicrobial agents have played a pivotal role in modern medicine by effectively controlling infections caused by bacteria, fungi, viruses, and other microorganisms. Their discovery revolutionized healthcare, enabling the successful treatment of diseases that were once life-threatening.[1] The use of antimicrobials dates back centuries, but it was not until the 19th century that their full potential was realized, leading to the development of antibiotics, antifungals, and antiviral drugs.[2,3] These agents are classified based on their mechanisms of action, including inhibition of cell wall synthesis, disruption of cell membrane integrity, suppression of protein synthesis, interference with nucleic acid synthesis, and inhibition of key metabolic pathways.[4,5] Despite the availability of diverse antimicrobial agents, their overuse and misuse have contributed to the emergence of antimicrobial resistance (AMR), a growing global health crisis.[6,7]

AMR arises through various molecular mechanisms, such as target site modification, enzymatic degradation of drugs, efflux pump activity, and reduced permeability to antimicrobial agents.[8, 9] These mechanisms may be intrinsic to bacteria or acquired through genetic exchange, allowing microorganisms to evade the effects of antimicrobial therapies.[10] The widespread use of antimicrobials in both human and veterinary medicine has exacerbated this issue, leading to the selection of resistant strains that can spread across populations and geographic regions.[11, 12] The World Health Organization (WHO) has recognized AMR as one of the most critical

public health threats of the 21st century, emphasizing the urgent need for coordinated global action to combat resistance.[13, 14]

The "One Health" approach, which integrates human, animal, and environmental health perspectives, has been advocated as a strategic framework to address AMR at multiple levels.[15,16] In addition to improving antimicrobial stewardship, efforts to educate prescribers and healthcare professionals about appropriate antimicrobial use are crucial to mitigating resistance.[17] The over-prescription and misuse of antibiotics in clinical settings have been driven by various factors, including economic considerations, lack of diagnostic capabilities, and patient expectations.[18,19] This underscores the importance of targeted educational programs to enhance knowledge, attitudes, and prescribing behaviors among healthcare workers.[20, 21]

Antimicrobial compounds are not only used for treating systemic infections but are also widely applied in wound care and surgical procedures.[22] Their role in preventing postoperative infections and facilitating complex medical interventions, such as organ transplantation and cancer treatment, cannot be overstated.[23,24] However, the continuous emergence of multidrug-resistant organisms has challenged the effectiveness of existing therapies, making it imperative to explore novel antimicrobial strategies and alternative therapeutic approaches.[25, 26] Research into the development of new antibiotics, antimicrobial peptides, bacteriophage therapy, and combination treatments is gaining momentum as part of the global response to AMR.[27, 28]

The emergence of drug resistance has accompanied the introduction of nearly every new antibiotic class, highlighting the need for sustainable antimicrobial development and stewardship.[29, 30] A major concern is the slow pace of new drug discovery and the reluctance of pharmaceutical industries to invest in antibiotic research due to economic constraints.[31, 32] Furthermore, antimicrobial resistance is not limited to clinical settings but extends to agriculture and the food chain, further complicating efforts to control its spread.[33, 34] Resistant bacteria from livestock and food products can transfer resistance genes to human pathogens, increasing the difficulty of treating common infections.[35, 36]

Given the alarming rise in resistant infections, addressing AMR requires a multi-faceted approach involving scientific research, policy interventions, and public awareness.[37, 38] Governments, healthcare organizations, and researchers must collaborate to implement stricter antibiotic regulations, promote responsible use, and accelerate the development of novel therapeutics.[39, 40] Surveillance systems must also be strengthened to track resistance patterns and inform treatment guidelines.[41, 42] Without urgent action, AMR could render many of the most effective medical treatments obsolete, leading to a future where even minor infections become untreatable.[43,44]

This chapter will explore the mechanisms of antimicrobial resistance, its impact on healthcare, and emerging therapeutic approaches to combat this growing threat. By understanding the complexities of AMR and implementing effective strategies, we can safeguard the efficacy of antimicrobial treatments and ensure better health outcomes for future generations.

Mechanisms of Antimicrobial Resistance

Antimicrobial resistance in bacteria occurs through four primary mechanisms: **limiting drug uptake, modifying drug targets, inactivating drugs, and actively expelling drugs through efflux pumps**. While intrinsic resistance primarily utilizes drug uptake limitation, drug inactivation, and efflux mechanisms, acquired resistance involves drug target modification, drug inactivation, and efflux. Gram-negative bacteria, due to their complex cell wall structure, employ all four mechanisms, whereas gram-positive bacteria rely on a subset of these strategies.

Limiting Drug Uptake

The ability of bacteria to restrict the uptake of antimicrobial agents plays a significant role in resistance. **Gram-negative bacteria**, due to their outer membrane composed of lipopolysaccharides (LPS), act as a selective barrier against large and hydrophilic molecules, inherently resisting certain classes of antibiotics. **Mycobacteria**, on the other hand, have an outer membrane rich in lipids, which facilitates the penetration of hydrophobic drugs like rifampicin and fluoroquinolones while restricting hydrophilic agents.

Some bacteria lack a traditional outer membrane entirely. **Mycoplasmas**, for example, do not possess a peptidoglycan cell wall, making them inherently resistant to **β-lactams and glycopeptides**, which target cell wall synthesis. Similarly, **Enterococci** exhibit intrinsic resistance to aminoglycosides because these polar molecules struggle to penetrate their thick cell wall. In recent years, **Staphylococcus aureus** has acquired resistance to vancomycin, a worrying trend in clinical settings.

Modification of Drug Targets

Many bacteria develop resistance by altering the structure of the antimicrobial target site. This modification reduces the drug's ability to bind effectively, diminishing its efficacy. Resistance through **target site alteration** is often caused by genetic mutations or acquisition of resistance genes through horizontal gene transfer mechanisms such as **conjugation, transduction, or transformation**.

One well-documented example is the mutation of **RNA polymerase and DNA gyrase**, leading to resistance against **rifamycins and quinolones**, respectively.

Similarly, **Staphylococcus aureus** acquires methicillin resistance through the **mecA gene**, which encodes an alternative penicillin-binding protein (PBP) that has a lower affinity for β-lactam antibiotics. Likewise, **Enterococci** develop glycopeptide resistance through the acquisition of **van genes**, which modify peptidoglycan precursors, rendering drugs like vancomycin ineffective.

Drug Inactivation

A common bacterial resistance mechanism involves **enzymatic degradation or modification** of antibiotics, rendering them inactive. This can occur through **hydrolysis, group transfer, or oxidation-reduction reactions**.

A classic example is **β-lactamase production**, which hydrolyzes the β-lactam ring of penicillins and cephalosporins, neutralizing their bactericidal effect. The genes encoding β-lactamases may be **chromosomal** or **plasmid-borne**, allowing for widespread dissemination. The first identified β-lactamase, **TEM-1**, is a major contributor to penicillin resistance.

Other resistance mechanisms include the ability of **Enterococci** to resist aminoglycosides, aztreonam, cephalosporins, and clindamycin through intrinsic resistance mechanisms. Meanwhile, **Staphylococcus aureus** resists penicillins by producing various **β-lactamases or modifying PBPs**, reducing drug binding efficiency.

Active Drug Efflux

Efflux pumps are **energy-dependent transport systems** that expel antibiotics from bacterial cells, thereby lowering intracellular drug concentration and minimizing their effectiveness. These efflux transporters, present in both gram-positive and gram-negative bacteria, do not modify or degrade the drug but simply prevent it from reaching its target.

Efflux transporters belong to five major families:

1. Major Facilitator Superfamily (MFS)
2. ATP-Binding Cassette (ABC) Superfamily
3. Small Multidrug Resistance (SMR) Family
4. Resistance-Nodulation-Division (RND) Superfamily
5. Multidrug and Toxic Compound Extrusion (MATE) Family

Small Multidrug Resistance (SMR) Family

SMR proteins are **the smallest bacterial multidrug efflux transporters** and are typically **proton-driven**. These transporters provide resistance to **quaternary ammonium compounds and other lipophilic cations** via an antiport mechanism. **EmrE**, a well-characterized SMR transporter, plays a role in resistance by exporting toxic compounds out of bacterial cells.

Major Facilitator Superfamily (MFS)

MFS is **the largest** group of secondary solute transporters. These transporters consist of **12 or 14 transmembrane segments** and function by utilizing ion gradients, particularly **sodium (Na+) or hydrogen (H+) ions**, to facilitate drug efflux. Many gram-positive and gram-negative bacteria use MFS transporters to resist drugs like tetracycline and fluoroquinolones.

Resistance-Nodulation-Division (RND) Transporters

RND efflux pumps are **primarily found in gram-negative bacteria** and can expel a broad range of **antibiotics and toxic compounds**. These efflux pumps form **tripartite complexes**, spanning both the **inner and outer bacterial membranes**, providing effective drug removal.

Common RND transporters include **AcrB, AdeB, CmeB, MexB, TtgB, SmeB, and MtrD**, all of which contribute to clinically relevant resistance. The expression of these efflux systems is tightly controlled by **transcriptional regulators** such as **AcrR, CmeR, NalC/NalD, TtgR, SmeT, and MtrR**.

Unlike other efflux transporters, **RND pumps** are structurally unique, forming complexes that bridge both the inner and outer membranes. This mechanism was first described by **Wandersman and colleagues** in the context of a protein-secreting apparatus of gram-negative bacteria.

ABC Transporter Family

Role in Antibiotic Production

ABC transporters have been extensively studied in producer organisms responsible for synthesizing various anti-tumor agents, such as daunorubicin and mithramycin. Additionally, they have been identified in the production of ionophore polyethers like tetronasin and macrotetrolide, as well as inhibitors of protein synthesis. A dendrogram analysis illustrates the relationships among the hydrophobic membrane components of type I and III ABC transporters derived from antibiotic-producing actinomycetes.

Structure of the ABC Transporter Family

ABC transporters consist of integral membrane proteins that actively transport various molecules across cellular membranes. These transporters play a crucial role in microbial defense mechanisms, particularly in antibiotic-producing organisms, where they facilitate self-resistance by expelling toxic compounds.

Gram-Positive and Gram-Negative Bacteria

Gram-Positive Bacteria

Gram-positive bacteria are a major concern in hospital-acquired infections, particularly in the United States. The prevalence of antibiotic-resistant strains, such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE), has been increasing. Approximately 60% of *Staphylococcus* infections in intensive care units (ICUs) are now attributed to MRSA.

The Gram-positive bacterial cell envelope serves as the first line of defense against external threats. *Staphylococcus aureus* exemplifies this structure, which includes a peptidoglycan layer, teichoic acids (TAs), and a capsule. The modification of TAs through d-alanylation and lysylphosphatidylglycerol synthesis plays a role in antibiotic resistance. Additionally, envelope stress response regulators enable bacteria to adapt to toxic conditions.

Gram-Negative Bacteria

The Gram staining method, developed by Hans Christian Gram in 1884, differentiates bacteria based on cell wall composition. Gram-positive bacteria retain a violet stain due to their thick peptidoglycan layer, whereas Gram-negative bacteria do not, appearing pink after counterstaining with safranin.

Antimicrobial resistance (AMR) in Gram-negative bacilli (GNB) is a significant challenge in ICUs. These bacteria are responsible for 45–70% of ventilator-associated pneumonia (VAP), 20–30% of catheter-related bloodstream infections, and other ICU-acquired sepsis cases such as surgical site and urinary tract infections.

Therapeutic Approaches to Combat Antimicrobial Resistance

Historical Perspective

Antimicrobial agents have revolutionized medicine, significantly improving life expectancy. One of the earliest treatments was Salvarsan, developed for syphilis. The discovery of penicillin by Alexander Fleming in 1928 marked a turning point in antibiotic therapy, followed by the synthesis of sulfonamides in 1935. The period from the 1950s to the 1970s, known as the "golden era" of antibiotics, saw the discovery of numerous antibiotic classes, including streptomycin from *Streptomyces griseus*.

Novel Strategies to Overcome AMR

Several alternative approaches are being explored to address antimicrobial resistance, including:

1. **Antimicrobial nanoparticles** – Designed to target drug-resistant bacteria.
2. **Bacteriophage therapy** – Uses viruses to selectively target and lyse pathogenic bacteria.
3. **Anti-biofilm agents** – Prevent the formation of bacterial biofilms that contribute to resistance.
4. **Efflux pump inhibitors** – Block bacterial mechanisms that expel antibiotics, increasing drug efficacy.
5. **Enzyme inhibitors** – Target bacterial enzymes responsible for antibiotic degradation.

Combination Therapy with Conventional Antibiotics

Combination therapy, although not always superior to monotherapy, can reduce the likelihood of resistance development. For instance, tuberculosis treatment relies on combination regimens to prevent resistance. Such strategies could be extended to other infections, particularly in immunocompromised patients.

β-Lactamase Inhibitors

β-lactamase inhibitors are widely used to counteract bacterial resistance to β-lactam antibiotics. These inhibitors, including clavulanic acid, sulbactam, and tazobactam, prevent bacterial β-lactamases from degrading antibiotics, thus restoring their effectiveness.

Drug Delivery Strategies

A major challenge in antibiotic therapy is poor cellular penetration. Advanced drug delivery systems, such as nanoparticle carriers, improve antibiotic transport into bacterial cells, enhancing treatment effectiveness.

Antivirulence Compounds

Unlike traditional antibiotics, antivirulence compounds do not kill bacteria directly. Instead, they inhibit pathogenicity mechanisms, allowing the host immune system to clear infections more effectively without promoting resistance.

Bacteriophage Therapy

Phage therapy is a promising alternative to antibiotics, particularly for multidrug-resistant infections. Bacteriophages are highly specific, targeting only pathogenic bacteria while sparing beneficial microbiota. This therapy has been successfully used in Eastern Europe and is gaining renewed interest globally.

Sonodynamic Antimicrobial Chemotherapy (SACT)

SACT is an emerging therapy that uses ultrasound waves combined with sonosensitizers to produce reactive oxygen species, which selectively kill bacterial cells. Compared to antimicrobial photodynamic therapy (aPDT), SACT has better tissue penetration, making it a promising alternative.

CONCLUSION

Bacteria are highly adaptable and capable of developing resistance to antimicrobial agents. With the rise of multidrug-resistant pathogens, innovative solutions are urgently needed. While the discovery of new antibiotics remains essential, alternative strategies such as bacteriophage therapy, enzyme inhibitors, drug delivery advancements, and sonodynamic chemotherapy offer promising avenues. The fight against antimicrobial resistance requires a multifaceted approach, combining scientific innovation, responsible antibiotic use, and improved healthcare practices.

The Ongoing Battle Against Antimicrobial Resistance

Bacteria are incredibly adaptable organisms, constantly evolving mechanisms to survive even the most potent antimicrobial treatments. The rise of multidrug-resistant (MDR) pathogens poses a significant threat to global health, making infections more difficult—and sometimes impossible—to treat with conventional antibiotics. As resistance continues to outpace the development of new

antibiotics, it is evident that a broader, more innovative approach is required to combat this growing crisis.

Exploring New Frontiers in Treatment

While the discovery and development of novel antibiotics remain crucial, alternative therapeutic strategies have gained increasing attention. Among these, bacteriophage therapy offers a highly specific method of targeting resistant bacteria without disrupting beneficial microbiota. Enzyme inhibitors, particularly β-lactamase inhibitors, continue to play a vital role in restoring the efficacy of existing antibiotics. Additionally, advancements in drug delivery systems, such as nanoparticles and targeted transport mechanisms, enhance the penetration and effectiveness of antimicrobial agents.

Harnessing Modern Technologies

Beyond conventional treatments, emerging technologies provide promising solutions to antimicrobial resistance (AMR). Sonodynamic antimicrobial chemotherapy (SACT) leverages ultrasound waves to activate antimicrobial agents within infected tissues, offering a non-invasive yet highly effective approach. Similarly, anti-virulence compounds aim to neutralize bacterial pathogenicity rather than killing the bacteria outright, reducing the selective pressure that drives resistance development.

A Multifaceted Approach for Sustainable Solutions

The fight against antimicrobial resistance requires more than just scientific breakthroughs. A comprehensive strategy must include:

- **Prudent Antibiotic Use:** Healthcare providers and patients must adopt responsible antibiotic-prescribing and usage practices to minimize unnecessary exposure to these drugs.
- **Increased Research and Development:** Governments, pharmaceutical companies, and research institutions must collaborate to accelerate the discovery of novel antimicrobial agents and alternative treatments.
- **Global Surveillance and Policy Implementation:** Strengthening monitoring systems and enforcing policies to regulate antibiotic use in both human medicine and agriculture will be critical in reducing resistance.
- **Public Awareness and Education:** Educating communities about the dangers of antibiotic misuse and the importance of infection prevention can help reduce the overall burden of resistant infections.

Looking Ahead: The Future of Antimicrobial Resistance

Despite the challenges posed by antibiotic-resistant bacteria, scientific advancements and innovative approaches offer hope for the future. The road ahead requires global cooperation, sustained research efforts, and a commitment to developing sustainable solutions. While bacteria will continue to evolve, our ability to adapt and counteract resistance will determine the success of future healthcare interventions. By embracing a multidimensional approach—combining new treatments, responsible antibiotic use, and proactive policies—we can work toward preserving the effectiveness of antimicrobial therapies for generations to come.

REFERENCES

1. Spring J. History of antimicrobial discovery and development. J Infect Dis., 1975; 132(5): 591-603.
2. Fleming A. Discovery of penicillin and its impact. Br J Med., 1945; 1(4361): 1-6.
3. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev., 2010; 74(3): 417-433.
4. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T., 2015; 40(4): 277-283.
5. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol., 2015; 13(1): 42-51.
6. Lerminiaux NA, Cameron AD. Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol., 2019; 65(1): 34-44.
7. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Rev Antimicrob Resist., 2016; 1-84.
8. World Health Organization. Global action plan on antimicrobial resistance. WHO, 2015.
9. CDC. The One Health approach to antibiotic resistance. CDC, 2017.
10. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect., 2017; 23(11): 793-798.
11. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ., 2010; 340: c2096.
12. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis., 2013; 13(12): 1057-1098.
13. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis., 2009; 49(10): 1541-1549.
14. Tacconelli E, Magrini N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO, 2017.
15. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis., 2016; 16(2): 239-251.
16. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr., 2016; 4(2): 1-37.
17. Theuretzbacher U, Outterson K, Engel A, Karlen A. The global preclinical antibacterial pipeline. Nat Rev Microbiol., 2020; 18(5): 275-285.
18. Woolhouse M, Ward M, Van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock, and the wider environment. Philos Trans R Soc Lond B

Biol Sci., 2015; 370(1670): 20140083.
19. Laxminarayan R, Van Boeckel T, Teillant A. The economic cost of antibiotic resistance. Lancet Glob Health, 2016; 4(1): e2-e3.
20. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med., 2013; 368(4): 299-302.
21. World Health Organization. Antimicrobial resistance surveillance. WHO, 2019.
22. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Glob Infect Dis., 2019; 11(1): 36-42.
23. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis., 2009; 48(1): 1-12.
24. Ventola CL. The antibiotic resistance crisis: part 2: management strategies and new agents. P T., 2015; 40(5): 344-352.
25. Wright GD. Something old, something new: revisiting natural products in antibiotic drug discovery. Can J Microbiol., 2014; 60(3): 147-154.
26. Singh R, Ledesma KR, Chang KT, Tam VH. Impact of pharmacodynamics on the emergence of resistance: a single-cell perspective. Infect Dis Ther, 2017; 6(2): 73-83.
27. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov., 2013; 12(5): 371-387.
28. Bush K, Page MG. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J Pharmacokinet Pharmacodyn, 2017; 44(1): 113-132.
29. McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr., 2018; 6(2): 1-26.
30. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol., 2007; 3(9): 541-548.
31. Lin J, Nishino K, Roberts MC, et al. Mechanisms of antibiotic resistance. Front Microbiol 2015; 6: 34.
32. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis., 2008; 197(8): 1079-1081.
33. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis., 2018; 18(3): 318-327.
34. Martínez JL. General principles of antibiotic resistance in bacteria. Drug Discov Today Technol., 2014; 11: 33-39.
35. van Duijn PJ, Dautzenberg MJ, Oostdijk EA. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care, 2011; 17(6): 658-665.
36. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis., 2019; 19(1): 56-66.
37. De Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med., 2016; 13(11): e1002184.
38. Shallcross LJ, Davies DS. Antibiotic overuse: a key driver of antimicrobial resistance. Br J Gen Pract., 2014; 64(629): 604-605.
39. O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review on Antimicrobial Resistance, 2014; 1-20.
40. Nathan C, Cars O. Antibiotic resistance—problems, progress, and prospects. N Engl J Med., 2014; 371(19): 1761-1763.
41. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med., 2010; 362(19): 1804-1813.
42. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines, and international responses. Int J Antimicrob Agents, 2012; 39(4): 295-299.
43. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health, 2015; 109(7): 309-318.
44. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet, 2016; 387(10014): 176-187.
45. Ramya P, Vasanth PM, Prasad PV, Babu SV Qualitative phytochemical screening tests of Alpinia galanga L. World Journal of Pharmaceutical Research, 2019; 8(5): 1064-1077.
46. Deepthi V, Rao PK, Vasanth PM Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis. Our Dermatol Online, 2014; 5(2): 118-123.
47. Prasanthi, R. M., Vasanth, P. M., & Ramesh, T. Assays for oxidative stress and antioxidant status. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2013; 4(1): 846-856.